TY - JOUR
T1 - Results of radiation therapy for superficial esophageal cancer using the standard radiotherapy method recommended by the Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group
AU - Nemoto, Kenji
AU - Yamada, Shogo
AU - Nishio, Masamichi
AU - Aoki, Masahiko
AU - Nakamura, Ryuji
AU - Matsumoto, Yasuo
AU - Sasamoto, Ryuta
AU - Saitoh, Yoshihiro
AU - Takayama, Makoto
AU - Mitsuhashi, Norio
AU - Gomi, Kohtaro
AU - Kanesaka, Naoto
AU - Kobayashi, Masao
AU - Ohnishi, Hiroshi
AU - Sasaki, Shigeru
AU - Tamamura, Hiroyasu
AU - Mitsumori, Michihide
AU - Nishimura, Yasumasa
AU - Tsujino, Kayoko
AU - Takemoto, Mitsuhiro
AU - Uchida, Nobue
AU - Yamamoto, Michinori
AU - Shioyama, Yoshiyuki
AU - Hirakawa, Kohichi
AU - Ono, Seiji
PY - 2006/3
Y1 - 2006/3
N2 - Background: Superficial esophageal cancer (SEC) is defined as esophageal cancer limited to the submucosal layers, including mucosal cancer and submucosal cancer, and is squamous cell carcinoma in most patients. In 2000, the Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group for SEC published a consensus guideline of standard radiotherapy methods. In this study, the interim treatment outcomes of SEC patients, who had received radiation therapy following the standard radiotherapy methods, were investigated. Patients and Methods: From 2000 to 2003, a total of 141 SEC patients were treated in 24 institutions in Japan. Results: The 1-, 2- and 3-year survival rates were 95%, 90% and 90%, respectively, for patients with mucosal cancer and 90%, 81% and 70%, respectively, for patients with submucosal cancer. The overall survival was better in patients who had undergone chemotherapy than in patients who had received radiation therapy alone, though the difference was not statistically significant. The clinical target volume (CTV) did not influence overall survival and intracavitary irradiation did not influence the local control rate in either patients with mucosal or submucosal cancer. Radiation-induced esophageal ulcer was not observed in this series. Conclusion: The standard radiotherapy methods are safe and effective for treating SEC. However, the usefulness of chemotherapy and intracavitary irradiation and the optimal setting of the CTV should be clarified by future randomized trials.
AB - Background: Superficial esophageal cancer (SEC) is defined as esophageal cancer limited to the submucosal layers, including mucosal cancer and submucosal cancer, and is squamous cell carcinoma in most patients. In 2000, the Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group for SEC published a consensus guideline of standard radiotherapy methods. In this study, the interim treatment outcomes of SEC patients, who had received radiation therapy following the standard radiotherapy methods, were investigated. Patients and Methods: From 2000 to 2003, a total of 141 SEC patients were treated in 24 institutions in Japan. Results: The 1-, 2- and 3-year survival rates were 95%, 90% and 90%, respectively, for patients with mucosal cancer and 90%, 81% and 70%, respectively, for patients with submucosal cancer. The overall survival was better in patients who had undergone chemotherapy than in patients who had received radiation therapy alone, though the difference was not statistically significant. The clinical target volume (CTV) did not influence overall survival and intracavitary irradiation did not influence the local control rate in either patients with mucosal or submucosal cancer. Radiation-induced esophageal ulcer was not observed in this series. Conclusion: The standard radiotherapy methods are safe and effective for treating SEC. However, the usefulness of chemotherapy and intracavitary irradiation and the optimal setting of the CTV should be clarified by future randomized trials.
UR - http://www.scopus.com/inward/record.url?scp=33645804046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645804046&partnerID=8YFLogxK
M3 - Article
C2 - 16619565
AN - SCOPUS:33645804046
VL - 26
SP - 1507
EP - 1512
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 2 B
ER -